Alvotech Announces Strategic Refinancing Agreement
June 07, 2024 04:00 ET
|
Alvotech
REYKJAVIK, Iceland, June 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech gengur frá samningi við alþjóðlega fjárfesta um endurfjármögnun skulda
June 07, 2024 04:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið hafi gert samning um endurfjármögnun skulda við GoldenTree Asset Management, bandarískt eignastýringarfyrirtæki, sem fer fyrir hópi alþjóðlegra...
Alvotech Announces Strategic Refinancing Agreement
June 07, 2024 04:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a...
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 29, 2024 08:05 ET
|
Alvotech
REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies í New York dagana 5.-6. júní 2024
May 29, 2024 08:04 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tekur í heilbrigðisráðstefnu Jefferies fjárfestingabankans, í New York dagana 5.-6. júni nk. Alvotech mun halda kynningu og funda með fjárfestum og viðskiptavinum á...
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 29, 2024 08:04 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024 17:15 ET
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period...
Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
May 21, 2024 17:14 ET
|
Alvotech
Heildartekjur á fyrsta ársfjórðungi 2024 jukust í 37 milljónir dollara, úr 16 milljónum dollara á sama tímabili í fyrraFramlegð á fyrsta fjórðungi 2024 var 17 milljónir dala, sem er 40 milljóna...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024 17:14 ET
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last...
Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu
May 21, 2024 08:01 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gert samstarfssamning við Dr. Reddy’s Laboratories SA, dótturfyrirtæki Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) um sölu- og...